Cell penetrating anti-guanosine antibody based therapy for cancers with Ras mutations
US10040867B2 · kind B2 · utility
1Cited by
4References
35Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 4, 2015 |
| Grant date | Aug 7, 2018 |
| Priority date | — |
| Expiry date | Mar 4, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/82
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
It has been established that cancer cells with oncogenic mutants in the small GTPase K-Ras are susceptible to antibodies that bind intracellular guanosine, but delivery of antibodies into cells can be challenging. A subset of lupus autoantibodies is associated with anti-guanosine activity, and is capable of cellular penetration. These antibodies have potential as therapeutic agents targeted towards K-Ras associated malignancies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.